• Skin Diseases
    • Peter C M Van De Kerkhof
    • Peter C M van de Kerkhof: Influence Statistics

      Peter C M van de Kerkhof

      Peter C M van de Kerkhof

      Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands | Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Peter C M van de:Expert Impact

      Concepts for whichPeter C M van dehas direct influence:Skin diseases,Patients psoriasis,Scalp psoriasis,Calcipotriol ointment,Psoriasis patients,Epidermal proliferation,Plaque psoriasis,Atopic dermatitis.

      Peter C M van de:KOL impact

      Concepts related to the work of other authors for whichfor which Peter C M van de has influence:Psoriatic arthritis,Patients psoriasis,Atopic dermatitis,Skin diseases,Quality life,Photodynamic therapy,Monoclonal antibodies.

      KOL Resume for Peter C M van de Kerkhof


      Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands


      Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.


      Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands


      Radboud University Medical Center, Nijmegen, The Netherlands


      Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands, View further author information


      Radboud Institute for Molecular Life Sciences (RIMLS), and, Radboud Institute for Health Sciences (RIHS), Nijmegen, Philips Research Eindhoven, Philips Electronics Nederland B.V., Eindhoven, and, RiverD International B.V., Rotterdam, The Netherlands


      Afdeling Dermatologie, Radboudumc, Huispostnummer 374, Postbus 9101, 6500 HB, Nijmegen, Nederland

      Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Departments of, Medical Psychology, Dermatology and, Health Evidence, Radboud university medical center, and, Department of Dermatology, Canisius-Wilhelmina Hospital, Nijmegen, Department of Dermatology, Rijnstate Hospital, Velp, and, Department of Dermatology, Ziekenhuisgroep Twente, Almelo, The Netherlands

      Department of Dermatology, Radboud university medical center


      Radboud University Medical Center, Department of Dermatology, Nijmegen, The Netherlands


      Dept of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands


      Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands


      Dermatology Department, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands


      Departments of Dermatology.

      Department of Dermatology, Radboud University Nijmegen Medical Centre, 6525 GL Nijmegen, the Netherlands


      Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

      University Hospital Nijmegen, Nijmegen, the Netherlands (P.K.)

      Departments of Dermatology


      Dermatologikum, Hamburg, Germany;, University Hospital Sint-Rafaël, Leuven, Belgium;, University Hospital, Nijmegen, and, Wyeth Research, Hoofddorp, The Netherlands;, Wyeth Research, Paris, France;, Wyeth Research, Collegeville, Pa., USA

      Department of Dermatology, 370 Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands


      Department of Dermatology, UMC St Radboud, PO Box 9101, 65 HB Nijmegen, the Netherlands


      Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, 652 GA, Nijmegen, The Netherlands


      Department of Dermatology, Radboud University Nijmegen, Medical Center, Nijmegen, The Netherlands


      Department of Dermatology, Radboud University Nijmegen Medical Centre, GL Nijmegen, The Netherlands


      From the Department of Dermatology, University Medical Center Nijmegen The Netherlands


      Departments of Dermatology and

      From Waterlooa; University of Western Ontariob; Virga Jesse Ziekenhuis, Hasseltc; Bispebjerg Hospital, Copenhagend; University Hospital Kuopioe; Hopital Saint Eloi, Montpellierf; Klinikum der Goethe-Universität, Frankfurtg; Hume St Hospital, Dublinh; Kliniek voor Huidziekten, Nijmegeni; Sentralsjukehuset i Møre og Romsdal, Ålesundj; Universital Hospital, Lundk; Dermatologische Klinik Universitätsspital Zürichl; Leo Pharmaceuticalsm; Hammersmith Hospital, London.n

      Sample of concepts for which Peter C M van de Kerkhof is among the top experts in the world.
      Concept World rank
      tacalcitol proliferation #1
      standardized injury #1
      single expression extent #1
      treatments ltb4induced inflammatory #1
      dithranol irritation patients #1
      treg psoriatic skin #1
      vivo cd11b upregulation #1
      psoriasis clearance time #1
      relapsing psoriasis #1
      psoriatic lesion psoriasis #1
      dermis cd45ro cells #1
      adalimumab treatment parameters #1
      16 weeks cyclosporin #1
      pharmacological effects vml #1
      fluorescence psoriasis #1
      treatment rambazole #1
      patients dithranol #1
      etanercept efalizumab #1
      fdap pdt #1
      bexarotene epidermal proliferation #1
      week biologicnaïve #1
      immunoglobulin tofacitinib #1
      betamethasone dipropionate treatment #1
      iqr median pga #1
      proliferation keratinization #1
      vivo diagnosis bcc #1
      ww reasons #1
      effectiveness leg elevation #1
      general strategy implementation #1
      margin psoriasis plaque #1
      frozen sections hbd2 #1
      k19 acitretin #1
      positive influence treatments #1
      patients skin diseases #1
      psoriasis childhood psoriasis #1
      tcf active interventions #1
      dithranol patients #1
      proliferation extension #1
      sites psoriasis lesion #1
      dithranol cream treatment #1
      pmn day #1
      keratin egfr expression #1
      nkreceptors #1
      intraepidermal neoplasias #1
      vml placebotreated patients #1
      differentiation 3 months #1
      psoriasis etanercept treatment #1
      mtx mtxsparing #1
      tcell subsets pb #1
      iqr pga #1

      Prominent publications by Peter C M van de Kerkhof

      KOL-Index: 28325

      BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis.

      METHODS: In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), eligible patients were aged 18 years or older, had a confirmed diagnosis of ...

      Known for Placebo Etanercept | Patients Ixekizumab | 2 Weeks | Nonsteroidal Antibodies | Phase 3
      KOL-Index: 24855

      BACKGROUND: New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.

      METHODS: In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-week, non-inferiority trial, adult patients with chronic stable plaque ...

      Known for Tofacitinib Etanercept | Placebo Patients | Chronic Plaque | Phase 3 | 5 10
      KOL-Index: 18714

      BACKGROUND: T-cell infiltration in plaque psoriasis has recently been an important subject of investigation. Interestingly, comparative analyses of the disease-specific composition of the lesional T-cell infiltrate in plaque psoriasis and other inflammatory dermatoses have only sparsely been performed.

      OBJECTIVES: To compare plaque psoriasis vs. atopic dermatitis and lichen ruber planus with respect to T-cell subsets, epidermal proliferation and keratinization.


      Known for Lichen Planus | Atopic Dermatitis | Plaque Psoriasis | Epidermal Proliferation | Cell Subsets
      KOL-Index: 17595

      BACKGROUND: Knowledge about quality of life and sexual health in patients with genital psoriasis is limited.

      OBJECTIVES: We studied quality of life and sexual function in a large group of patients with genital psoriasis by means of validated questionnaires. In addition, we evaluated whether sufficient attention is given by healthcare professionals to sexual problems in patients with psoriasis, as perceived by the patients.

      METHODS: A self-administered questionnaire was sent to 1579 ...

      Known for Sexual Health | Genital Psoriasis | Quality Life | Psychological Surveys | Validated Questionnaires
      KOL-Index: 17224

      BACKGROUND: Knowledge on the sequential treatment of psoriasis with biologics with regard to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in patients previously treated with etanercept. The relationship between the reasons for discontinuation of etanercept and the response to adalimumab is not clear in psoriasis.

      OBJECTIVES: To evaluate the efficacy and safety of adalimumab in patients with psoriasis with primary failure, secondary failure or ...

      Known for Patients Psoriasis | Secondary Failure | Etanercept Adalimumab | Monoclonal Antibodies | Efficacy Safety
      KOL-Index: 16071

      BACKGROUND: Physical symptoms of skin diseases have been shown to negatively affect patients' wellbeing. Although insight into physical symptoms accompanying skin diseases is relevant for the management and treatment of skin diseases, the prevalence of physical symptoms among patients with skin diseases is a rather unexplored territory.

      OBJECTIVES: The goal of the present study was to examine the prevalence of physical symptoms of itch, pain and fatigue in patients with skin ...

      Known for Skin Diseases | Physical Symptoms | Fatigue Patients | Itch Pain | General Practice
      KOL-Index: 16003

      BACKGROUND: In previous studies, etanercept 25 mg twice weekly (BIW) or 50 mg BIW significantly reduced disease severity in patients with plaque psoriasis and demonstrated a favourable safety profile.

      OBJECTIVES: To assess the efficacy and safety of etanercept 50 mg administered once weekly (QW) compared with placebo in patients with moderate-to-severe plaque psoriasis over 24 weeks.

      METHODS: This study was conducted in two parts: (i) a 12-week, double-blind, placebo-controlled phase, in ...

      Known for Etanercept 50 | Plaque Psoriasis | Week Patients | Placebo Qw | Baseline Pasi
      KOL-Index: 15959

      Physical complaints, such as pain, can be effectively reduced by placebo effects through induction of positive expectations, or increased by nocebo effects through induction of negative expectations. In the present study, verbally induced nocebo and placebo effects on itch were experimentally investigated for the first time. In part 1, the role of verbal suggestions in inducing nocebo effects on itch and pain was investigated. All subjects received the same somatosensory quantitative ...

      Known for Verbal Suggestions | Placebo Effects | Itch Pain | Histamine Application | Induction Nocebo
      KOL-Index: 15403

      BACKGROUND: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis.

      METHODS: We randomly assigned 903 patients with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 ...

      Known for Ustekinumab Etanercept | Pasi Week | 75 Improvement | Patients Psoriasis | Monoclonal Antibodies
      KOL-Index: 14290

      BACKGROUND: Chronic skin diseases, such as atopic dermatitis and psoriasis, are known to affect quality of life by heightening psychological distress. Knowledge about factors contributing to psychological distress is essential for supporting physicians in diagnostic and multidisciplinary treatment options for patients psychologically at risk.

      OBJECTIVES: To examine whether generic physical, psychological and social factors relevant to patients with chronic diseases might contribute to ...

      Known for Psychological Distress | Atopic Dermatitis | Chronic Skin Diseases | Patients Psoriasis | Social Support
      KOL-Index: 13598

      BACKGROUND: Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients. To monitor this serial liver biopsies were performed. The Fibroscan and the Fibrotest are two novel, non-invasive methods that might be able to assess MTX-induced hepatic fibrosis.

      AIM: Evaluating the accuracy and feasibility of the Fibroscan and Fibrotest to detect significant MTX-induced liver fibrosis in psoriasis patients.

      METHODS: We assessed 24 psoriasis patients who had a recent liver ...

      Known for Psoriasis Patients | Liver Fibrosis | Fibroscan Fibrotest | Methotrexate Mtx | Noninvasive Methods
      KOL-Index: 13328

      The therapeutic efficacy and tolerability of calcipotriol ointment and betamethasone valerate ointment in psoriasis were compared in a multicentre, prospective, randomised, double-blind, right/left trial. 345 inpatients and outpatients with psoriasis vulgaris of symmetrical distribution were treated twice daily for 6 weeks with calcipotriol ointment 50 micrograms/g and betamethasone ointment 0.1% randomly assigned to opposite sides of the body. The main outcome measures--the psoriasis ...

      Known for Betamethasone Valerate | Psoriasis Vulgaris | 6 Weeks | Calcipotriol Ointment | Thickness Scaling
      KOL-Index: 13000

      BACKGROUND: Calcipotriol and betamethasone dipropionate are both widely used, effective treatments for psoriasis. Vitamin D analogues and topical corticosteroids have different mechanisms of action in the treatment of psoriasis. A new vehicle has been developed in order to contain both calcipotriol (50 micro g g-1) and betamethasone dipropionate (0.5 mg g-1) in an ointment form. By using calcipotriol and a corticosteroid together, greater efficacy may be achieved than by using either ...

      Known for Psoriasis Vulgaris | Efficacy Safety | Daily Calcipotriol | Betamethasone Dipropionate | Ointment Formulation
      KOL-Index: 12993

      The structure and function of the tumor microvasculature is of great interest for cancer biology, diagnosis, and therapy. The distribution of endothelial cells, pericytes, and basal lamina in tumors is not well documented. In this study, the authors investigated the distribution of markers for these different components in a series of malignant human tumors and in human granulation tissue, both situations with extensive angiogenesis. Their results show a striking heterogeneity in the ...

      Known for Granulation Tissue | Endothelial Cells | Differential Expression | Basal Lamina | Tumor Vasculature
      KOL-Index: 12833

      Placebo and nocebo effects are known to play a key role in treatment effects in a wide variety of conditions. These effects have frequently been investigated with regard to pain and also in other physical sensations, but have hardly been investigated with regard to itch. In addition, neither in pain nor in any other physical sensation, the single and combined contribution of the expectancy mechanisms of conditioning and verbal suggestion have ever been investigated in both placebo and ...

      Known for Verbal Suggestion | Nocebo Effects | Pain Itch | Physical Sensations | Conditioning Placebo

      Key People For Skin Diseases

      Top KOLs in the world
      Christopher Ernest Maitland Griffiths
      patients psoriasis retinoic acid human skin
      Roderick James Hay
      global burden skin disease tinea capitis
      Hywel C G Williams
      atopic eczema cochrane skin basal cell carcinoma
      David Joel Margolis
      atopic dermatitis united states pressure ulcers
      Donald Y M Leung
      atopic dermatitis eczema herpeticum food allergy
      John J Voorhees
      human skin retinoic acid ultraviolet irradiation

      Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands | Department of Dermatology, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. | Department of Dermatology, Radboud University Medical Center, Nijmege

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.